- ►ascopubs.org MA Cobleigh, CL Vogel, D Tripathy, NJ Robert … - Journal of Clinical Oncology, 1999 - jco.ascopubs.org PURPOSE: Overexpression of the HER2 protein occurs in 25% to 30% of human breast
cancers and leads to a particularly aggressive form of the disease. Efficacy and
safety of recombinant humanized anti-HER2 monoclonal antibody as a single ... Cited by 1567 - Related articles - BL Direct - All 11 versions
CL Shapiro, A Recht - The New England journal of medicine, 2001 - nejm.highwire.org Women with primary invasive breast cancer receive both local and systemic
treatment. Surgery and radiation therapy are local treatments given to reduce
the risk of recurrent cancer in the breast, chest wall, and regional lymph ... Cited by 186 - Related articles - BL Direct - All 7 versions
- ►ascopubs.org [PDF] CL Shapiro, PH Hardenbergh, R Gelman, D … - Journal of Clinical Oncology, 1998 - jco.ascopubs.org Purpose: To assess the cardiac effects of two differ- ent cumulative doses of
adjuvant doxorubicin and radia- tion therapy (RT) in breast cancer patients.
Patients and Methods: Two hundred ninety-nine breast cancer patients were ... Cited by 148 - Related articles - BL Direct - All 7 versions
GM Dubowchik, MA Walker - Pharmacology and Therapeutics, 1999 - Elsevier This review is a survey of various approaches to targeting cytotoxic anticancer
drugs to tumors primarily through biomolecules expressed by cancer cells or
associated vasculature and stroma. These include monoclonal antibody ... Cited by 145 - Related articles - BL Direct - All 6 versions
KR Hande - BBA-Gene Structure and Expression, 1998 - Elsevier Six antineoplastic agents, currently approved for cancer treatment by the United
States Food and Drug Administration (FDA), target topoisomerase II (Table 1).
Several other drugs which 'poison' topoisomerase II have demonstrated ... Cited by 144 - Related articles - All 5 versions
- ►ascopubs.org LCM Kremer, EC Van Dalen, M Offringa, J … - Journal of Clinical Oncology, 2001 - jco.ascopubs.org Add to CiteULike Add to Complore Add to Connotea Add to Del.icio.us Add to Digg
Add to Facebook Add to Reddit Add to Technorati Add to Twitter What's this? ...
From the Departments of Pediatric Oncology, Pediatric Cardiology, and ... Cited by 144 - Related articles - BL Direct - All 9 versions
- ►lsh.is [PDF] HJ Burstein, EP Winer - The New England journal of medicine, 2000 - nejm.highwire.org There are more than 2 million women in the United States alone who are living
with a history of breast cancer. 1 , 2 Screening programs have increased the
number of women in whom invasive or noninvasive breast cancer has been ... Cited by 141 - Related articles - BL Direct - All 9 versions
- ►oxfordjournals.org [PDF] G Berry, M Billingham, E Alderman, P … - Annals of Oncology, 1998 - Springer Background: Pegylated liposomal doxorubicin (PL-DOX) has been shown in
preclinical models to induce less cardiotoxicity than non-liposomal doxorubicin.
Endomyocardial biopsy is a highly sensitive and speci¢c method for ... Cited by 130 - Related articles - BL Direct - All 6 versions
- ►aacrjournals.org AC Childs, SL Phaneuf, AJ Dirks, T Phillips, … - Cancer research, 2002 - AACR There have been very few investigations as to whether mitochondrial-mediated
apoptosis in vivo is the underlying mechanism of doxorubicin cardiotoxicity.
Moreover, no investigations have been conducted to determine whether there ... Cited by 123 - Related articles - BL Direct - All 6 versions
- ►ahajournals.org T Levade, N Auge, RJ Veldman, O Cuvillier, A … - Circulation research, 2001 - Am Heart Assoc Sphingolipids have emerged as a new class of lipid mediators. In response to
various extracellular stimuli, sphingolipid turnover can be stimulated in
vascular cells and cardiac myocytes. Subsequent generation of sphingolipid ... Cited by 121 - Related articles - BL Direct - All 6 versions
